 |
Top 10 mRNA startups in USA
Oct 12, 2024 | By Jason Kwon | 25 |
1
Funding: $135M
City Therapeutics is a biopharmaceutical company focused on developing next-generation small interfering RNAs.
City Therapeutics is a biopharmaceutical company focused on developing next-generation small interfering RNAs.
2
Funding: $275.6M
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology.
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology.
3
Funding: $3.9B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
4
Funding: $480.9M
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
5
Funding: $449.5M
GreenLight Biosciences is using RNA to target some of the world’s biggest problems
GreenLight Biosciences is using RNA to target some of the world’s biggest problems
6
Funding: $442.6M
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
7
Funding: $433.5M
Dicerna Pharmaceuticals develops therapeutic agents in various disease areas based on dicer substrate technology platform. The company offers RNA interference (RNAi)-targeted drugs and delivery systems for therapeutic areas of oncology and metabolic diseases. It also provides Dicer Substrate Technology, a second generation of gene silencing, which triggers RNAi and is used in therapeutic areas, including inflammation, immunology, and cardiovascular diseases.
Dicerna Pharmaceuticals develops therapeutic agents in various disease areas based on dicer substrate technology platform. The company offers RNA interference (RNAi)-targeted drugs and delivery systems for therapeutic areas of oncology and metabolic diseases. It also provides Dicer Substrate Technology, a second generation of gene silencing, which triggers RNAi and is used in therapeutic areas, including inflammation, immunology, and cardiovascular diseases.
8
Funding: $360.1M
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment.
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment.
9
Funding: $332M
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
10
Funding: $321M
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
